175 related articles for article (PubMed ID: 18279502)
1. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
Ulmert D; Cronin AM; Björk T; O'Brien MF; Scardino PT; Eastham JA; Becker C; Berglund G; Vickers AJ; Lilja H
BMC Med; 2008 Feb; 6():6. PubMed ID: 18279502
[TBL] [Abstract][Full Text] [Related]
2. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
[TBL] [Abstract][Full Text] [Related]
3. Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.
Lilja H; Cronin AM; Dahlin A; Manjer J; Nilsson PM; Eastham JA; Bjartell AS; Scardino PT; Ulmert D; Vickers AJ
Cancer; 2011 Mar; 117(6):1210-9. PubMed ID: 20960520
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
Klein RJ; Hallden C; Gupta A; Savage CJ; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Wallström P; Vickers AJ; Lilja H
Eur Urol; 2012 Mar; 61(3):471-7. PubMed ID: 22101116
[TBL] [Abstract][Full Text] [Related]
5. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
6. Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort.
Larsen SB; Brasso K; Iversen P; Christensen J; Christiansen M; Carlsson S; Lilja H; Friis S; Tjønneland A; Dalton SO
Eur J Cancer; 2013 Sep; 49(14):3041-8. PubMed ID: 23684783
[TBL] [Abstract][Full Text] [Related]
7. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
Vickers AJ; Ulmert D; Sjoberg DD; Bennette CJ; Björk T; Gerdtsson A; Manjer J; Nilsson PM; Dahlin A; Bjartell A; Scardino PT; Lilja H
BMJ; 2013 Apr; 346():f2023. PubMed ID: 23596126
[TBL] [Abstract][Full Text] [Related]
8. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
[TBL] [Abstract][Full Text] [Related]
9. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
[TBL] [Abstract][Full Text] [Related]
10. [Serum markers for early detection and staging of prostate cancer. Status report on current and future markers].
Haese A; Graefen M; Palisaar J; Huland E; Huland H
Urologe A; 2003 Sep; 42(9):1172-87. PubMed ID: 14504750
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.
Spencer JA; Chng WJ; Hudson E; Boon AP; Whelan P
Br J Radiol; 1998 Nov; 71(851):1130-5. PubMed ID: 10434906
[TBL] [Abstract][Full Text] [Related]
12. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
13. Stage shift in PSA-detected prostate cancers - effect modification by Gleason score.
Pashayan N; Pharoah P; Neal DE; Hamdy F; Donovan J; Martin RM; Greenberg D; Duffy SW
J Med Screen; 2009; 16(2):98-101. PubMed ID: 19564523
[TBL] [Abstract][Full Text] [Related]
14. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
[TBL] [Abstract][Full Text] [Related]
15. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
D'Amico AV; Moul JW; Carroll PR; Sun L; Lubeck D; Chen MH
J Natl Cancer Inst; 2003 Sep; 95(18):1376-83. PubMed ID: 13130113
[TBL] [Abstract][Full Text] [Related]
16. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL.
Törnblom M; Norming U; Adolfsson J; Becker C; Abrahamsson PA; Lilja H; Gustafsson O
Urology; 1999 May; 53(5):945-50. PubMed ID: 10223488
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
[TBL] [Abstract][Full Text] [Related]
19. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.
Gann PH; Hennekens CH; Stampfer MJ
JAMA; 1995 Jan; 273(4):289-94. PubMed ID: 7529341
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
